Palisade Bio Inc PALI shares are trading lower by 0.66% to $0.75 Monday morning on downward momentum after the company last week announced a $2 million registered direct offering.
The company entered into definitive agreements with institutional investors for the purchase of 2,339,398 shares of common stock for gross proceeds of roughly $2 million in a registered direct offering.
Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the registered direct offering.
Palisade Bio intends to use the net proceeds from the financing for working capital and general corporate purposes.
According to data from Benzinga Pro, PALI has a 52-week high of $9.10 and a 52-week low of $0.55.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
